Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

"As a healthcare company with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...

Its Innovative Medicine division covers pharmaceuticals focusing on areas like immunology and oncology, alongside MedTech engaging in medical ... products and strategic market expansions. Johnson ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

Atlanta Hawks forward Jalen Johnson, already ruled out of Saturday night's home game against the Toronto Raptors, will continue to be sidelined as he has further medical testing on his injured ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...